Quick Answer
Corvus Pharmaceuticals, Inc. reported Operating Income Loss of -$42.97 million for the year ending 2025.
- Corvus Pharmaceuticals, Inc. showed a decrease of -56.0% in Operating Income Loss from 2024 to 2025.
- This data is from Corvus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Corvus Pharmaceuticals, Inc.'s Operating Income Loss has declined by 26,590.1%.
- Historical annual values: Fiscal year 2025: -$42.97 million | Fiscal year 2024: -$27.55 million | Fiscal year 2023: -$23.41 million | Fiscal year 2022: -$32.57 million | Fiscal year 2021: -$38.63 million | Fiscal year 2020: -$43.76 million | Fiscal year 2019: -$48.85 million | Fiscal year 2018: -$49.22 million | Fiscal year 2017: -$56.52 million | Fiscal year 2016: -$36.98 million | Fiscal year 2015: -$13.77 million | Fiscal year 2014: -$161.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: